A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose–response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose–response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.

[1]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[2]  A. Rong,et al.  Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials , 2013, Clinical Cancer Research.

[3]  C. Twelves,et al.  A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine , 2009, Clinical pharmacology and therapeutics.

[4]  B P Booth,et al.  Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[5]  Yu‐Nien Sun,et al.  Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer , 2010, Cancer Chemotherapy and Pharmacology.

[6]  Jan Fagerberg,et al.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Lena E Friberg,et al.  Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response , 2013, British journal of clinical pharmacology.

[8]  G. Demetri,et al.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.

[9]  J. Crowley,et al.  Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors , 2013, Clinical Cancer Research.

[10]  L E Friberg,et al.  A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis , 2014, CPT: pharmacometrics & systems pharmacology.

[11]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Nenad Sarapa,et al.  Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Ribba,et al.  Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor. , 2010, Urology.

[14]  France Mentré,et al.  Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches , 2015, The AAPS Journal.

[15]  D R Stanski,et al.  Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. , 1990, Anesthesiology.

[16]  Michael L Maitland,et al.  RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point. , 2012, Cancer research.

[17]  Johan Pallud,et al.  A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy , 2012, Clinical Cancer Research.

[18]  D. Ankerst,et al.  Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials , 2012, Clinical Cancer Research.

[19]  L E Friberg,et al.  PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST , 2013, CPT: pharmacometrics & systems pharmacology.

[20]  M. Karlsson,et al.  PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST , 2013, CPT: pharmacometrics & systems pharmacology.

[21]  R. Bruno,et al.  On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies , 2009, Clinical pharmacology and therapeutics.

[22]  J. Cuzick,et al.  Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.

[23]  B. Agoram,et al.  Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy , 2006, The AAPS Journal.

[24]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[25]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[27]  T. Fojo,et al.  Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. , 2011, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial , 2012, BMC Cancer.

[29]  N. Holford A Time to Event Tutorial for Pharmacometricians , 2013, CPT: pharmacometrics & systems pharmacology.

[30]  A. Iliadis,et al.  Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer , 2011, Cancer Chemotherapy and Pharmacology.

[31]  F J Lewis,et al.  Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.

[32]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Peter L. Bonate,et al.  Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[34]  J. Pérez-Ruixo,et al.  Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment , 2008, Cancer Chemotherapy and Pharmacology.

[35]  A. Ruffion,et al.  Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy , 2009, The Prostate.

[36]  Mats O. Karlsson,et al.  A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[37]  B. Ribba,et al.  A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients , 2014, The AAPS Journal.

[38]  J. Verweij,et al.  Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.

[39]  Dominique Barbolosi,et al.  Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy-Toxicity Mathematical Model , 2000, Comput. Biomed. Res..

[40]  Nicholas H G Holford,et al.  A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.

[41]  M. Maitland,et al.  Estimation of renal cell carcinoma treatment effects from disease progression modeling , 2012, Clinical pharmacology and therapeutics.